Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (NASDAQ:SLDB) Stock Price Up 5.5% on Analyst Upgrade
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of “Moderate Buy” by Brokerages
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences (NASDAQ:SLDB) Director Sells $46,400.20 in Stock
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of “Moderate Buy” by Analysts
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of “Moderate Buy” by Brokerages
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Present at Upcoming Scientific Meetings
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101